Gentrack extended its slump.
Automation and robotics company’s ownership structure strategic review still ongoing.
The US Food and Drug Administration has opened the door to a US$7b market.
Company apologises to disappointed shareholding travellers at today’s AGM.
Despite CEO Ross Taylor’s staunch defence of the company’s plumbing product, uncertainty remains about the causes and costs of a leaky pipe crisis in Australia.
After four long, difficult, expensive years since listing on the NZX, Cannasouth reckons it’s reached a turning point.
Saturday’s election result was broadly in line with expectations but a few sectors are primed to prosper under a change of government.
NZ-founded, ASX-listed chemicals group has lost its third director post-IPO.
Initial reaction strongly negative as market digests risks of Australian leaky pipes problem.
Insurance company’s underlying profit expected to be between $7m and $10m, including large events.
